Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome
Open Access
- 26 May 2021
- journal article
- research article
- Published by Springer Nature in Neurochemical Research
- Vol. 46 (9) , 2249-2261
Abstract
Dravet syndrome (DS) is a rare genetic encephalopathy that is characterized by severe seizures and highly resistant to commonly used antiepileptic drugs (AEDs). In 2020, FDA has approved fenfluramine (FFA) for treatment of seizures associated with DS. However, the clinically used FFA is a racemic mixture (i.e. (±)-FFA), that is substantially metabolized to norfenfluramine (norFFA), and it is presently not known whether the efficacy of FFA is due to a single enantiomer of FFA, or to both, and whether the norFFA enantiomers also contribute significantly. In this study, the antiepileptic activity of enantiomers of FFA (i.e. (+)-FFA and (−)-FFA) and norFFA (i.e. (+)-norFFA and (−)-norFFA) was explored using the zebrafish scn1Lab−/− mutant model of DS. To validate the experimental conditions used, we assessed the activity of various AEDs typically used in the fight against DS, including combination therapy. Overall, our results are highly consistent with the treatment algorithm proposed by the updated current practice in the clinical management of DS. Our results show that (+)-FFA, (−)-FFA and (+)-norFFA displayed significant antiepileptic effects in the preclinical model, and thus can be considered as compounds actively contributing to the clinical efficacy of FFA. In case of (−)-norFFA, the results were less conclusive. We also investigated the uptake kinetics of the enantiomers of FFA and norFFA in larval zebrafish heads. The data show that the total uptake of each compound increased in a time-dependent fashion. A somewhat similar uptake was observed for the (+)-norFFA and (−)-norFFA, implying that the levo/dextrotation of the structure did not dramatically affect the uptake. Significantly, when comparing (+)-FFA with the less lipophilic (+)-norFFA, the data clearly show that the nor-metabolite of FFA is taken up less than the parent compound.Keywords
Funding Information
- Chinese Scholarship Council doctoral fellowship (201606250020)
This publication has 34 references indexed in Scilit:
- Functional Characterisation of the Maturation of the Blood-Brain Barrier in Larval ZebrafishPLOS ONE, 2013
- Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatmentNature Communications, 2013
- Epileptic Encephalopathies: An OverviewEpilepsy Research and Treatment, 2012
- Successful use of fenfluramine as an add‐on treatment for Dravet syndromeEpilepsia, 2012
- Dravet syndrome historyDevelopmental Medicine & Child Neurology, 2011
- Serotonin and epilepsyJournal of Neurochemistry, 2006
- Embryonic and larval expression of zebrafish voltage‐gated sodium channel α‐subunit genesDevelopmental Dynamics, 2006
- (+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine TransportersThe Journal of Pharmacology and Experimental Therapeutics, 2003
- De novoSCN1Amutations are a major cause of severe myoclonic epilepsy of infancyHuman Mutation, 2003
- Comparative biodisposition and metabolism of14C-(±)-fenfluramine in mouse, rat, dog and manXenobiotica, 1992